Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Share Price Cross Below Two Hundred Day Moving Average – What’s Next?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $30.76 and traded as low as $29.59. Lakefront Biotherapeutics American Depositary Shares shares last traded at $29.60, with a volume of 200,611 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Wall Street Zen cut Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Morgan Stanley initiated coverage on Lakefront Biotherapeutics American Depositary Shares in a report on Friday, July 10th. They issued an “equal weight” rating and a $30.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $34.33.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

The company has a 50-day moving average of $28.60 and a 200-day moving average of $30.76. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -20.99 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.25 earnings per share for the quarter, topping the consensus estimate of ($1.27) by $1.52. The company had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $11.26 million. As a group, analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Hedge funds and other institutional investors have recently bought and sold shares of the company. ABC Arbitrage SA purchased a new stake in Lakefront Biotherapeutics American Depositary Shares in the 1st quarter valued at about $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Lakefront Biotherapeutics American Depositary Shares during the first quarter worth approximately $248,000. QRG Capital Management Inc. increased its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% during the 1st quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after buying an additional 3,535 shares during the last quarter. XTX Topco Ltd boosted its holdings in Lakefront Biotherapeutics American Depositary Shares by 92.6% in the fourth quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock valued at $759,000 after acquiring an additional 11,162 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Lakefront Biotherapeutics American Depositary Shares by 121.9% in the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after acquiring an additional 186,452 shares during the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.